6h agoStocktwits NewsBULLISH 73General
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.
Archived explainer. For the current picture see today's ABCL page.
Why Is ABCELLERA BIOLOGICS (ABCL) Stock Up Today?
By the Top Tier Newswire AI Desk · August 11, 2026 at 12:03 AM ET · reviewed against 15 wire stories
ABCELLERA BIOLOGICS (ABCL) is up +34.78% in the latest session. Our newswire has captured 15 stories on ABCL across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABCL stock surged 34.78% to $9.34 on Friday, driven by positive Phase 2 clinical trial results for its drug ABCL635, which showed a 50% greater reduction in hot flashes compared to placebo. The announcement marked a significant milestone for AbCellera Biologics, which reported the findings in an SEC 8-K filing and through multiple public disclosures. The stock’s sharp rise followed a broader upward trend, with the price climbing 57.5% over the previous eight sessions.
What Happened
AbCellera Biologics announced that its drug ABCL635 met primary endpoints in a Phase 2 trial, delivering statistically significant results in reducing moderate-to-severe hot flashes after a single dose. The drug demonstrated a 50% placebo-adjusted reduction in vasomotor symptoms, a key indicator of efficacy for non-hormonal menopause treatment. The results were disclosed in a slide deck published by the company and confirmed in an 8-K filing with the SEC. JonesResearch also raised its price target for ABCL from $13 to $25, signaling increased confidence in the stock’s potential. The news triggered a wave of buying, with the stock rising as much as 41% during the session.
What The Data Shows
The stock’s recent performance has been marked by strong upward momentum, with the price moving from $5.69 to $8.96 over the last eight sessions. Unusual options activity was also observed in the last 36 hours, with $256,000 in call premium traded versus $247,000 in put premium. The largest single options print was $256,000. Additionally, insider transactions showed a director, John S. Montalbano, buying shares on May 14, 2026, and no insider sales in the last 90 days. The company remains unprofitable with a net margin of -248.8% and a trailing 12-month revenue increase of 101.3%, but the recent drug data has clearly shifted market sentiment.
What To Watch
AbCellera Biologics has no scheduled earnings report in the near term. Investors should monitor the breadth of analyst coverage and any further developments in the regulatory or partnership landscape for ABCL635.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABCL by the numbers
Last: $9.34Session: +34.78%7 sessions: +57.47%Coverage: 15 stories / 11 sourcesAI sentiment: 68/100 (bullish)Mkt cap: $2.0B52w: $2.75 to $8.44
The headlines behind the move
13h agoThe FlyBULLISH 61Analyst
Abcellera Price Target Raised To 25 From 13 At Jonesresearch
15h agoSeeking AlphaBULLISH 55Product/PR
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes - Slideshow
2026-08-10. The following slide deck was published by AbCellera Biologics Inc.
16h agoBloombergBULLISH 78Product/PR
AbCellera (ABCL) Stock Jumps 41% After Hot Flash Drug Trial Success
Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial.
18h agoMarketChameleonBULLISH 73Product/PR
ABCL635 Delivers Statistically Significant Phase 2 Results—50% Greater Reduction in Hot Flashes Over Placebo August 10, 2026
AbCellera’s ABCL635 achieves a notable 50% placebo-adjusted reduction in frequency of moderate-to-severe vasomotor symptoms (hot flashes) after a single dose, marking a landmark in non-hormonal menopause treatment with strong efficacy and tolerability from its Phase 2 clinical trial.
18h agoSeeking AlphaBULLISH 78Product/PR
AbCellera surges on positive mid-stage results for menopause drug ABCL635
AbCellera (ABCL) stock jumps 35% after positive Phase 2 ABCL635 menopause hot flash data, showing strong symptom reductions vs placebo—read the update.
20h agoInvestorsHubBULLISH 73Earnings
AbCellera shares surge 22% after ABCL635 delivers positive Phase 2 results
AbCellera (NASDAQ:ABCL) shares surge 22% after ABCL635 meets its Phase 2 endpoints, significantly reducing menopause-related hot flashes and symptom severity.
21h agoSEC 8-KNEUTRAL 50General
AbCellera Biologics Inc. (ABCL) files 8-K
Filed: 2026-08-10 AccNo: 0001703057-26-000053 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ABCL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ABCL move explainers: 2026-08-11 · 2026-08-10 · 2026-07-20